Vivimed Labs share price
NSE: VIVIMEDLABBSE: 532660Pharmaceuticals & BiotechnologySmall Cap
Last close ₹6.09down ₹0.12 (1.93%)BSE ₹6.11
Share price at the NSE close on 23 Oct 2026. Previous close ₹6.21.
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹50 Cr3,293rd largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit.
- No recent results
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet.
- No recent results
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- Volume, NSEVolume. Shares traded on the last trading day.
- 75
Results
Consolidated; ₹ crore, the charts by years to March, the table by quarter.Quarterly results
Quarter to Mar 2026, against the quarter beforeFiled 17 Jul
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹12 Crdown 24.95%
- Net profitNet profit. Under it, net profit in the quarter before. A change in per cent is not worked out where either period is a loss or nothing.
- −₹146 CrQuarter to Dec 2025: −₹17 Cr
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax.
- −1,217.0%
Revenue by year
Net profit by year, a loss in red
- Net profit
- Loss
A loss in 7 of the 10 years shown
The years either side of a change of basis do not compare. From the year to Mar 2019, the company reports a discontinued business.
| ₹ crore | Jun 2024Filed 18 Jan | Sep 2024Filed 17 Jan | Dec 2024Filed 15 Feb | Mar 2025Filed 21 Jul | Jun 2025Filed 14 Aug | Sep 2025Filed 14 Nov | Dec 2025Filed 13 Mar | Mar 2026Filed 17 Jul |
|---|---|---|---|---|---|---|---|---|
| Revenue | 29 | 25 | 37 | 26 | 21 | 21 | 16 | 12 |
| Net profit | −15 | −5 | −6 | −5 | −5 | −7 | −17 | −146 |
| Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. | −51.9% | −20.8% | −16.4% | −20.1% | −25.7% | −35.4% | −103.5% | −1,217.0% |
Consolidated. The last eight quarters. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, PHARMA, which carries all its revenue.
Valuation
Today, against the company's own history. Not shown, P/E: no results for a period ending in the last six months, or nine for a company filing half-yearly. Not shown, P/B: no results for a period ending in the last six months, or nine for a company filing half-yearly. Not shown, EV/EBITDA: no results for a period ending in the last six months, or nine for a company filing half-yearly. Its history crosses a change of basis in the accounts in the year to Mar 2019: days before it are of the company before the change.PE ratio and valuation history
Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price. When a year's dividend goes ex later than the year before's, the yield reads zero for the days between; a run of under 60 such trading days is left out of the yield's medians and percentiles. The ex-date is the day from which a buyer of the share no longer gets the dividend.
At or below today's level on 72% of 1,769 trading days over the last 10 years.
LowestHighest
Its median0.00%Industry median0.53%
Peers and competitors
Pharmaceuticals, 216 listed companies, priced on 23 Oct 2026. The table lists the 8 companies closest to Vivimed Labs in market cap.
Vivimed Labs is not on the chart: it has no P/E or return on equity today
| Company | |||||||||
|---|---|---|---|---|---|---|---|---|---|
 Zenith DrugsZENITHDRUG | 68 | 17.2 | 0.9 | – | +28.4% | −44.9% | 5.5% | – | 0.00% |
 Onyx BiotecONYX | 67 | – | 1.2 | – | +12.1% | −104.3% | −0.4% | – | 0.00% |
 PhaarmasiaPHRMASI | 62 | 3.5 | 2.8 | 28.6 | +111.8% | – | 114.5% | 7.1% | 0.00% |
 Rekvina LaboratoriesVINRKLB | 62 | – | – | – | – | – | – | −139.0% | 0.00% |
 Biofil Chemicals & PharmaceuticalsBIOFILCHEM | 47 | 97.0 | 2.2 | 59.5 | +9.3% | −82.7% | 2.4% | 2.1% | 0.00% |
 Mangalam Drugs and OrganicsMANGALAM | 45 | – | 0.4 | – | −22.3% | – | −30.3% | −12.9% | 0.00% |
 ANG Lifesciences IndiaANG | 43 | – | 0.8 | – | −15.6% | – | −22.8% | −6.3% | 0.00% |
 Vasundhara RasayansVRL | 43 | 7.3 | 1.0 | 6.8 | +3.5% | +49.9% | 15.4% | 13.3% | 1.48% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Dividends
Per share, by the year it was paid for, and the latest payments.Dividend history and dates
| Ex-date | Type | Per share |
|---|---|---|
| 19 Sep 2018 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.40 |
| 21 Sep 2017 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹0.40 |
| 24 Sep 2014 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.00 |
| 24 Sep 2013 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.00 |
| 21 Sep 2012 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹3.00 |
| 26 Sep 2011 | FinalFinal dividend. Called final by its date: the company did not say which kind it was, and it went ex within six months after the company's year end, the time in which the annual general meeting that declares the final dividend must be held. | ₹2.00 |
Latest payments, as declared, by ex-date.
Latest announcements
Routine notices left out.Share news and announcements
Oct 2026
22 Oct · Legal
Exchange has sought clarification from Vivimed Labs Limited for the quarter ended 31-Mar-2026 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. The company has not submitted the Statement of Impact of Audit Qualifications in case of modified opinion(s) The response of the Company is awaited.15 Oct · Board meeting
Sep 2026
28 Sep · Updates
Aug 2026
Vivimed Labs share price by year
Each calendar year to 2025.Vivimed Labs share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 17.67 | – | 26.60 | 17.67 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 18 Dec 2025.
Recent sessions
The last 10 trading days to 23 Oct 2026, as traded on NSE.
| Date | Open | High | Low | Close | Average price | Volume |
|---|---|---|---|---|---|---|
| 23 Oct 2026 | 6.09 | 6.09 | 6.09 | 6.09 | 6.09 | 75 |
| 22 Oct 2026 | 6.30 | 6.30 | 6.21 | 6.21 | 6.28 | 12,106 |
| 21 Oct 2026 | 6.35 | 6.40 | 6.33 | 6.33 | 6.36 | 12,147 |
| 19 Oct 2026 | 6.46 | 6.46 | 6.45 | 6.45 | 6.45 | 4,193 |
| 16 Oct 2026 | 6.70 | 6.70 | 6.58 | 6.58 | 6.60 | 14,210 |
| 15 Oct 2026 | 6.84 | 6.84 | 6.71 | 6.71 | 6.79 | 4,256 |
| 14 Oct 2026 | 6.84 | 6.84 | 6.84 | 6.84 | 6.84 | 3,786 |
| 13 Oct 2026 | 6.97 | 6.98 | 6.97 | 6.97 | 6.97 | 5,077 |
| 12 Oct 2026 | 7.25 | 7.39 | 7.11 | 7.11 | 7.28 | 1,74,714 |
| 9 Oct 2026 | 7.25 | 7.25 | 6.57 | 7.25 | 7.21 | 9,65,168 |
Prices in ₹ per share as traded, not adjusted.
Price adjustments
What the price chart is corrected for, so it reads as one share held throughout.Stock split history
| Ex-date | Event | Price factor | What happened |
|---|---|---|---|
| 18 Dec 2025 | Price move | – | This is the share's first trade after a corporate action (Annual General Meeting, ex-date 27 Dec 2024), and the action's terms do not account for the move. Earlier prices are not shown. |
| 20 Jun 2022 | Price move | – | Between two trading sessions the price moved by a fifth or more. The company made an announcement in time for trading that day or the trading day before. Not adjusted for. |
| 6 Apr 2016 | Split | 0.2000 | Each share became 5. |
| 26 Jul 2013 | Price move | – | Between two trading sessions the price moved by a fifth or more. No corporate action is on record. Not adjusted for. |
Earlier prices are multiplied by the factor, so the chart reads as one share held throughout. Where an event has no factor that can be worked out, the chart leaves out the closes before it. Any other event is noted and not adjusted for.
Company details
- Legal name
- Vivimed Labs Limited
- NSE symbol
- VIVIMEDLAB
- BSE code
- 532660
- ISIN
- INE526G01021
- Industry
- Pharmaceuticals & Biotechnology
- Listed
- Aug 2005
- Face value
- ₹2
- CIN
- L02411KA1988PLC009465
- Corporate identity number, the registrar of companies' code for it